

## Teva to apply Insilico's predictive Digital Twins for biopharmaceutical production

22 February 2019 | News

**Insilico's solutions for predictive biomanufacturing are one of the key technologies to form higher quality therapies and bring them faster to market.**



Insilico Biotechnology AG and Teva Pharmaceutical Industries Ltd. have announced an agreement to apply Insilico's technology for predictive biomanufacturing to create and implement more efficient production processes of Teva's biopharmaceutical therapeutics.

The ever increasing demand of high-quality biopharmaceutical therapies such as monoclonal antibodies requires more than ever highly efficient and robust production technologies. Simultaneously the digital transformation of the biopharmaceutical sector generates tremendous amounts of data from bioprocessing which represent an enormous value to be capitalized on.

Insilico's solutions for predictive biomanufacturing are one of the key technologies to convert this value into higher quality therapies and to bring them faster to market. Insilico's Digital Twins of biopharmaceutical production processes employ metabolic models of producer organisms in combination with flexible process models and artificial intelligence to create optimized production processes by computational simulations.

As a leading provider of high-quality medicines for nearly all therapeutic areas, Teva uses the most efficient and innovative technologies for best-in-class production of their therapeutic agents.

The collaboration will run for three years and will be based at Insilico's sites in Stuttgart, Germany and at Teva's West

Chester, PA, USA, location.